ArticleFrontiers in public health2021

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis.

Peng-Fei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.